Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c

Halozyme Reports Third Quarter 2016 Financial Results

November 7, 2016 4:05 PM EST

SAN DIEGO, Nov. 7, 2016 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results and recent highlights for the third quarter ended September 30.

"The third quarter was highlighted by Genentech's BLA filing for rituximab in a subcutaneous formulation using Halozyme's ENHANZE platform in multiple blood cancers, a development that adds to the potential for our royalty revenue and highlights the benefits of our business model," said Dr. Helen Torley, president and chief executive officer. "In our oncology pillar, we continued initiation of our global sites in our phase... More